Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Proc Natl Acad Sci U S A ; 118(27)2021 07 06.
Article in English | MEDLINE | ID: mdl-34183414

ABSTRACT

Demyelination is a key pathogenic feature of multiple sclerosis (MS). Here, we evaluated the astrocyte contribution to myelin loss and focused on the neurotrophin receptor TrkB, whose up-regulation on the astrocyte finely demarcated chronic demyelinated areas in MS and was paralleled by neurotrophin loss. Mice lacking astrocyte TrkB were resistant to demyelination induced by autoimmune or toxic insults, demonstrating that TrkB signaling in astrocytes fostered oligodendrocyte damage. In vitro and ex vivo approaches highlighted that astrocyte TrkB supported scar formation and glia proliferation even in the absence of neurotrophin binding, indicating TrkB transactivation in response to inflammatory or toxic mediators. Notably, our neuropathological studies demonstrated copper dysregulation in MS and model lesions and TrkB-dependent expression of copper transporter (CTR1) on glia cells during neuroinflammation. In vitro experiments evidenced that TrkB was critical for the generation of glial intracellular calcium flux and CTR1 up-regulation induced by stimuli distinct from neurotrophins. These events led to copper uptake and release by the astrocyte, and in turn resulted in oligodendrocyte loss. Collectively, these data demonstrate a pathogenic demyelination mechanism via the astrocyte release of copper and open up the possibility of restoring copper homeostasis in the white matter as a therapeutic target in MS.


Subject(s)
Astrocytes/metabolism , Astrocytes/pathology , Copper/metabolism , Multiple Sclerosis/metabolism , Animals , Biological Transport , Chronic Disease , Cicatrix/pathology , Cuprizone , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental , Humans , Inflammation/pathology , Ligands , Membrane Transport Proteins/metabolism , Mice, Knockout , Myelin Sheath/metabolism , Nerve Growth Factors/metabolism , Receptor, trkB/metabolism , Up-Regulation , White Matter/pathology
2.
Molecules ; 25(22)2020 Nov 18.
Article in English | MEDLINE | ID: mdl-33218208

ABSTRACT

Astrocytes greatly participate to inflammatory and neurotoxic reactions occurring in neurodegenerative diseases and are valuable pharmacological targets to support neuroprotection. Here we used human astrocytes generated from reprogrammed fibroblasts as a cellular model to study the effect of the compound Laquinimod and its active metabolite de-Laquinimod on astrocyte functions and the astrocyte-neuron interaction. We show that human iAstrocytes expressed the receptor for the inflammatory mediator IL1 and responded to it via nuclear translocation of NFκB, an event that did not occur if cells were treated with Laquinimod, indicating a direct anti-inflammatory activity of the drug on the human astrocyte. Similarly, while exposure to IL1 downregulated glial glutamate transporters GLAST and GLT1, treatment with Laquinimod supported maintenance of physiological levels of these proteins despite the inflammatory milieu. Laquinimod also induced nuclear translocation of the aryl hydrocarbon receptor (AHR), suggesting that drug action was mediated by activation of the AHR pathway. However, the drug was effective despite AHR inhibition via CH223191, indicating that AHR signaling in the astrocyte is dispensable for drug responses. Finally, in vitro experiments with rat spinal neurons showed that laquinimod did not exert neuroprotection directly on the neuron but dampened astrocyte-induced neurodegeneration. Our findings indicate that fibroblast-derived human astrocytes represent a suitable model to study astrocyte-neuron crosstalk and demonstrate indirect, partial neuroprotective efficacy for laquinimod.


Subject(s)
Astrocytes/metabolism , Inflammation/pathology , Neurotoxins/toxicity , Quinolones/pharmacology , Amino Acid Transport System X-AG/metabolism , Animals , Astrocytes/drug effects , Humans , Induced Pluripotent Stem Cells/drug effects , Induced Pluripotent Stem Cells/metabolism , Interleukin-1beta/metabolism , NF-kappa B/metabolism , Nerve Degeneration/pathology , Quinolones/chemistry , Rats, Sprague-Dawley , Receptors, Aryl Hydrocarbon/metabolism , Signal Transduction/drug effects
3.
Drug Dev Ind Pharm ; 43(9): 1480-1488, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28406045

ABSTRACT

OBJECTIVE: Aim of this work was the synthesis of a methacrylic hyaluronic acid (HA) derivative and the production, via photocrosslinking, of related hydrogels loaded with an endopeptidase intended for a potential oral treatment of celiac disease. METHODS: The methacrylic derivative of HA was prepared through a one-pot procedure involving the reaction with ethylenediamine (EDA) and methacrylic anhydride (MA). The obtained derivative, named HA-EDA-MA, was used to prepare photocrosslinked hydrogels loaded with a prolyl endopeptidase derived from Flavobacterium meningosepticum (PEP FM) able to detoxify gliadin. Obtained hydrogels were recovered as gels or freeze-dried powders. RESULTS: Hydrogels obtained as freeze-dried powders, are able to protect loaded enzyme from degradation due to freeze-drying process and from alteration during storage, overall in the presence of a cryoprotectant. All photocrosslinked HA-EDA-MA hydrogels (gels and powders) release PEP FM in simulated intestinal fluid in sustained manner and in active form. HA-EDA-MA hydrogels are nontoxic as demonstrated through in vitro studies on BALB 3T3 cells. CONCLUSIONS: Prepared hydrogels show a potential application for oral treatment of celiac disease thanks to the possibility to release enzymes able to detoxify the gliadin peptide that induces the immunogenic response.


Subject(s)
Celiac Disease/drug therapy , Ethylenediamines/chemistry , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/pharmacology , Hydrogels/chemistry , Methacrylates/administration & dosage , Methacrylates/pharmacology , Serine Endopeptidases/chemistry , Administration, Oral , Animals , Celiac Disease/pathology , Humans , Mice , Prolyl Oligopeptidases
4.
Int J Pharm ; 491(1-2): 359-66, 2015 Aug 01.
Article in English | MEDLINE | ID: mdl-26140987

ABSTRACT

High-mobility group box 1 (HMGB1) is a nonhistone protein secreted by airway epithelial cells in hyperinflammatory diseases such as asthma. In order to down-regulate HMGB1 expression in airway epithelial cells, siRNA directed against HMGB1 was delivered through nanocomplexes based on a cationic copolymer of poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) by using H441 cells. Two copolymers were used in these experiments bearing respectively spermine side chains (PHEA-Spm) and both spermine and PEG2000 chains (PHEA-PEG-Spm). PHEA-Spm and PHEA-PEG-Spm derivatives complexed dsDNA oligonucleotides with a w/w ratio of 1 and higher as shown by a gel retardation assay. PHEA-Spm and PHEA-PEG-Spm siRNA polyplexes were sized 350-650 nm and 100-400 nm respectively and ranged from negativity/neutrality (at 0.5 ratio) to positivity (at 5 ratio) as ζ potential. Polyplexes formed either at a ratio of 0.5 (partially complexing) or at the ratio of 5 (fully complexing) were tested in subsequent experiments. Epifluorescence revealed that nanocomplexes favored siRNA entry into H441 cells in comparison with naked siRNA. As determined by flow cytometry and a trypan blue assay, PHEA-Spm and PHEA-PEG-Spm allowed siRNA uptake in 42-47% and 30% of cells respectively, however only with PHEA-Spm at w/w ratio of 5 these percentages were significantly higher than those obtained with naked siRNA (20%). Naked siRNA or complexed scrambled siRNA did not exert any effect on HMGB1mRNA levels, whereas PHEA-Spm/siRNA at the w/w ratio of 5 down-regulated HMGB1 mRNA up to 58% of control levels (untransfected cells). PEGylated PHEA-Spm/siRNA nanocomplexes were able to down-regulate HMGB1 mRNA levels up to 61% of control cells. MTT assay revealed excellent biocompatibility of copolymer/siRNA polyplexes with cells. In conclusion, we have found optimal conditions for down-regulation of HMGB1 by siRNA delivery mediated by polyaminoacidic polymers in airway epithelial cells in the absence of cytotoxicity. Functional and in-vivo studies are warranted.


Subject(s)
Epithelial Cells/metabolism , Mammaglobin A/biosynthesis , Peptides/chemistry , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/pharmacology , Cell Line, Tumor , DNA/metabolism , Down-Regulation/drug effects , Epithelial Cells/drug effects , Gene Transfer Techniques , Humans , Materials Testing , Nanostructures , Polyhydroxyethyl Methacrylate/analogs & derivatives , RNA, Small Interfering/metabolism , Respiratory Mucosa/cytology , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism , Transfection
5.
Biomacromolecules ; 15(11): 4351-62, 2014 Nov 10.
Article in English | MEDLINE | ID: mdl-25322257

ABSTRACT

In this work we wish to report on the covalent functionalization of polylactide (PLA) surfaces by photoradical thiol-yne to yield antibacterial surfaces. At first, hydrophilic and hydrophobic thiol fluorescent probes are synthesized and used to study and optimize the conditions of ligation on alkyne-PLA surfaces. In a second part, a new antibacterial polyaspartamide copolymer is covalently grafted. The covalent surface modification and the density of surface functionalization are evaluated by SEC and XPS analyses. No degradation of PLA chains is observed, whereas covalent grafting is confirmed by the presence of S2p and N1s signals. Antiadherence and antibiofilm activities are assessed against four bacterial strains, including Gram-negative and Gram-positive bacteria. A strong activity is observed with adherence reduction factors superior to 99.98% and biofilm formation decreased by 80%. Finally, in vitro cytocompatibility tests of the antibacterial surfaces are performed with L929 murine fibroblasts and show cell viability without promoting proliferation.


Subject(s)
Anti-Bacterial Agents/chemistry , Peptides/chemistry , Photochemistry/methods , Polyesters/chemistry , Sulfhydryl Compounds/chemistry , Animals , Anti-Bacterial Agents/metabolism , Cell Line , Mice , Peptides/metabolism , Polyesters/metabolism , Sulfhydryl Compounds/metabolism , Surface Properties
6.
J Exp Med ; 211(1): 29-43, 2014 Jan 13.
Article in English | MEDLINE | ID: mdl-24344238

ABSTRACT

Axonal sorting is a crucial event in nerve formation and requires proper Schwann cell proliferation, differentiation, and contact with axons. Any defect in axonal sorting results in dysmyelinating peripheral neuropathies. Evidence from mouse models shows that axonal sorting is regulated by laminin211- and, possibly, neuregulin 1 (Nrg1)-derived signals. However, how these signals are integrated in Schwann cells is largely unknown. We now report that the nuclear Jun activation domain-binding protein 1 (Jab1) may transduce laminin211 signals to regulate Schwann cell number and differentiation during axonal sorting. Mice with inactivation of Jab1 in Schwann cells develop a dysmyelinating neuropathy with axonal sorting defects. Loss of Jab1 increases p27 levels in Schwann cells, which causes defective cell cycle progression and aberrant differentiation. Genetic down-regulation of p27 levels in Jab1-null mice restores Schwann cell number, differentiation, and axonal sorting and rescues the dysmyelinating neuropathy. Thus, Jab1 constitutes a regulatory molecule that integrates laminin211 signals in Schwann cells to govern cell cycle, cell number, and differentiation. Finally, Jab1 may constitute a key molecule in the pathogenesis of dysmyelinating neuropathies.


Subject(s)
Axons/physiology , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Neurogenesis/physiology , Peptide Hydrolases/metabolism , Schwann Cells/physiology , Animals , Blotting, Western , Body Weights and Measures , Bromodeoxyuridine , COP9 Signalosome Complex , Cell Differentiation/physiology , Cell Proliferation , Immunohistochemistry , In Situ Nick-End Labeling , Intracellular Signaling Peptides and Proteins/genetics , Laminin/metabolism , Mice , Mice, Knockout , Peptide Hydrolases/genetics , Rotarod Performance Test
7.
Biomacromolecules ; 14(12): 4260-70, 2013 Dec 09.
Article in English | MEDLINE | ID: mdl-24164546

ABSTRACT

Novel amphiphilic copolymers have been synthesized based on a biocompatible poly(hydroxyethylaspartamide) (PHEA) backbone, bearing both anchoring groups for gold nanoparticles, such as thiols and disulfide, and conjugable moieties, such as amino groups, the latter as points suitable for appending further functional agents. The strategy was to functionalize α,ß-poly[(N-2-hydroxyethyl)-D,L-aspartamide] (PHEA) with PEG2000-NH2 and with ethylenediamine (EDA) obtaining a partially pegylated copolymer with a large number of pendant primary amino groups. A fraction of the latter was conjugated with molecules bearing terminal thiol moieties such as 12-mercaptododecanoic acid (MDA) and disulfide groups such as lipoic acid (LA), obtaining the two amphiphilic derivatives PHEA-PEG2000-EDA-MDA (PPE-MDA) and PHEA-PEG2000-EDA-LA (PPE-LA), which also proved intrinsically able to self-assemble in polymeric micelles. The two copolymers efficiently coated gold nanostars (GNSs, size ≈ 40 nm), wrapping around the surface increasing only slightly the hydrodynamic diameter (reaching ≈ 45 nm), imparting them stability and a pH-switchable surface charge, due to the unreacted amino groups. Remarkably, the poor solvation and the huge steric hindrance experienced by the amino groups lowers the observed logarithmic protonation constants to 5.6-5.7. In vitro experiments demonstrated that PPE-MDA and PPE-LA copolymers have an intrinsic excellent biocompatibility in both the human brain neuroblastoma (SH-SY5Y) and human bronchial epithelial (16-HBE) cell lines. Interaction of the same cell lines with "nude" GNS and GNS coated with PPE-LA was also studied, disclosing a completely satisfactory biocompatibility of the latter.


Subject(s)
Coated Materials, Biocompatible/chemical synthesis , Gold/chemistry , Metal Nanoparticles/chemistry , Peptides/chemistry , Polyethylene Glycols/chemistry , Surface-Active Agents/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Coated Materials, Biocompatible/toxicity , Ethylenediamines/chemistry , Humans , Materials Testing , Metal Nanoparticles/toxicity , Metal Nanoparticles/ultrastructure , Particle Size
8.
Biomacromolecules ; 14(6): 1838-49, 2013 Jun 10.
Article in English | MEDLINE | ID: mdl-23621358

ABSTRACT

Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, that is, ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. This latter was obtained by chemical reaction of α,ß-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-dl-aspartamide (PHEA-EDA) with polylactic acid (PLA), and subsequent reaction with lactose, obtaining PHEA-EDA-PLA-GAL copolymer. To enhance the entrapment into obtained nanostructures, a hydrophobic RBV prodrug, that is, RBV tripalmitate, was synthesized and its capability to release RBV in the presence of an adequate enzymatic activity was demonstrated. Liver-targeted RBV tripalmitate-loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration value with nanometric size. By in vitro experiments, the specificity of RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles toward HepG2 was demonstrated by using a competitive inhibition assay in the presence of free GAL. This finding raises hope in terms of future micelles-based liver-targeted drug delivery strategy for the hepatitis C treatment.


Subject(s)
Antiviral Agents/chemistry , Galactose/chemistry , Liver/drug effects , Micelles , Prodrugs , Ribavirin/chemistry , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Hep G2 Cells , Humans , Magnetic Resonance Spectroscopy , Ribavirin/administration & dosage , Ribavirin/pharmacology , Spectroscopy, Fourier Transform Infrared
9.
Front Neuroanat ; 6: 41, 2012.
Article in English | MEDLINE | ID: mdl-23087618

ABSTRACT

Animal models provide an important tool to investigate the pathogenesis of neuromuscular disorders. In the present study, we analyze fiber composition of the brachial plexus branches to the pectoral muscles: the medial anterior thoracic nerve (MATN) and the lateral anterior thoracic nerve (LATN). The morphological and morphometric characteristics and the percentage of motor fibers within each nerve are here reported, adding information to microscopic anatomy knowledge of the rat brachial plexus. As control, we employed the quadriceps nerve, commonly used for the evaluation of motor fibers at hindlimbs. We demonstrated that the MATN and the LATN are predominantly composed of large motor fibers and therefore could be employed to evaluate the peripheral nervous system (PNS) involvement at forelimbs in neurological diseases models, predominantly affecting the motor fiber compartment.

10.
Macromol Biosci ; 12(6): 770-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22496104

ABSTRACT

The ability of a hydrogel obtained by crosslinking INUDV and PEGBa to facilitate sustained release of flutamide is examined. The hydrogel is prepared in pH = 7.4 PBS and no toxic solvents or catalysts are used. It is recovered in microparticulate form and its size distribution is determined. Mucoadhesive properties are evaluated in vitro by reproducing gastrointestinal conditions. Flutamide is loaded into the hydrogel using a post-fabrication encapsulation procedure that allows a drug loading comparable to that of market tablets. Drug-loaded microparticles are orally administered to cross-bred dogs and the in vivo study demonstrates their ability to prolong the half-life of the principal active metabolite approximately threefold and to significantly increase its bioavailability.


Subject(s)
Androgen Antagonists , Drug Delivery Systems/methods , Flutamide , Hydrogels , Hypoglycemic Agents , Insulin , Administration, Oral , Androgen Antagonists/chemistry , Androgen Antagonists/pharmacokinetics , Androgen Antagonists/pharmacology , Animals , Biological Availability , Dogs , Flutamide/chemistry , Flutamide/pharmacokinetics , Flutamide/pharmacology , Half-Life , Hydrogels/chemical synthesis , Hydrogels/chemistry , Hydrogels/pharmacokinetics , Hydrogels/pharmacology , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/pharmacology , Insulin/chemistry , Insulin/pharmacokinetics , Insulin/pharmacology , Male
11.
J Drug Target ; 20(5): 433-44, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22533704

ABSTRACT

New fluorinated amphiphilic copolymers based on a biocompatible polyaspartamide have been prepared in order to obtain polymeric micelles useful for delivering anticancer drugs. In particular, α,ß-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) has been derivatized with polyethylene glycol (PEG(2000)) and ethylendiamine (EDA). Both these portions form the hydrophilic part of the copolymer, while the hydrophobic moiety is given by 1,2,4-oxadiazoles: 5-pentafluorophenyl-3-perfluoroheptyl-1,2,4-oxadiazole (PPOX) or 3-carboxyethyl-5-pentadecafluoroheptyl-1,2,4-oxadiazole (CPOX). Copolymers named PHEA-PEG(2000)-EDA-PPOX and PHEA-PEG(2000)-EDA-CPOX have been prepared with various degrees of derivatization and characterized by spectroscopic analyses. Size exclusion chromatography, pyrene colorimetric assay, light scattering analysis and scanning electron microscopy have evidenced the occurrence of a self-association process in aqueous medium. The ability of these aggregates to incorporate a hydrophobic drug and increase its solubility has been evaluated by using Flutamide, a fluorinated anticancer agent. Moreover, the activity of Flutamide-loaded micelles on proliferation of dihydrotestosterone stimulated LNCaP cells has been determined and compared to that of free drug.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Drug Delivery Systems , Flutamide/administration & dosage , Polymers/chemistry , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Chromatography, Gel , Dihydrotestosterone/pharmacology , Drug Carriers/chemistry , Ethylenediamines/chemistry , Flutamide/chemistry , Flutamide/pharmacology , Humans , Hydrophobic and Hydrophilic Interactions , Male , Micelles , Microscopy, Electron, Scanning , Oxadiazoles/chemistry , Peptides/chemistry , Polyethylene Glycols/chemistry , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Solubility
12.
Development ; 139(7): 1359-67, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22357929

ABSTRACT

Myelination is a complex process that requires coordinated Schwann cell-axon interactions during development and regeneration. Positive and negative regulators of myelination have been recently described, and can belong either to Schwann cells or neurons. Vimentin is a fibrous component present in both Schwann cell and neuron cytoskeleton, the expression of which is timely and spatially regulated during development and regeneration. We now report that vimentin negatively regulates myelination, as loss of vimentin results in peripheral nerve hypermyelination, owing to increased myelin thickness in vivo, in transgenic mice and in vitro in a myelinating co-culture system. We also show that this is due to a neuron-autonomous increase in the levels of axonal neuregulin 1 (NRG1) type III. Accordingly, genetic reduction of NRG1 type III in vimentin-null mice rescues hypermyelination. Finally, we demonstrate that vimentin acts synergistically with TACE, a negative regulator of NRG1 type III activity, as shown by hypermyelination of double Vim/Tace heterozygous mice. Our results reveal a novel role for the intermediate filament vimentin in myelination, and indicate vimentin as a regulator of NRG1 type III function.


Subject(s)
Gene Expression Regulation, Developmental , Myelin Sheath/metabolism , Peripheral Nerves/metabolism , Vimentin/physiology , ADAM Proteins/metabolism , ADAM17 Protein , Animals , Axons/metabolism , Coculture Techniques , Cytoskeleton/metabolism , Heterozygote , Humans , Mice , Mice, Inbred C57BL , Neuregulin-1/metabolism , Rats , Schwann Cells/cytology
13.
Exp Neurol ; 214(2): 276-84, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18809400

ABSTRACT

The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs. This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid. Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons. Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties. In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity. Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin. These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.


Subject(s)
Mitochondria/drug effects , Neuroprotective Agents/pharmacology , Peripheral Nervous System Diseases/pathology , Sensory Receptor Cells/drug effects , Sensory Receptor Cells/pathology , Thioctic Acid/pharmacology , Animals , Antineoplastic Agents/toxicity , Antineoplastic Agents, Phytogenic/toxicity , Antioxidants/pharmacology , Apoptosis/drug effects , Axons/pathology , Axons/ultrastructure , Cells, Cultured , Cisplatin/toxicity , Ganglia, Spinal/cytology , Iron-Binding Proteins/metabolism , Membrane Potentials/drug effects , Mitochondria/pathology , Paclitaxel/toxicity , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/drug therapy , Rats , Schwann Cells/cytology , Sensory Receptor Cells/ultrastructure , Frataxin
14.
J Cell Sci ; 119(Pt 19): 3981-93, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16988027

ABSTRACT

Axonal loss causes disabling and permanent deficits in many peripheral neuropathies, and may result from inefficient nerve regeneration due to a defective relationship between Schwann cells, axons and the extracellular matrix. These interactions are mediated by surface receptors and transduced by cytoskeletal molecules. We investigated whether peripheral nerve regeneration is perturbed in mice that lack glial fibrillary acidic protein (GFAP), a Schwann-cell-specific cytoskeleton constituent upregulated after damage. Peripheral nerves develop and function normally in GFAP-null mice. However, axonal regeneration after damage was delayed. Mutant Schwann cells maintained the ability to dedifferentiate but showed defective proliferation, a key event for successful nerve regeneration. We also showed that GFAP and the other Schwann-cell-intermediate filament vimentin physically interact in two distinct signaling pathways involved in proliferation and nerve regeneration. GFAP binds integrin alphavbeta8, which initiates mitotic signals soon after damage by interacting with fibrin. Consistently, ERK phosphorylation was reduced in crushed GFAP-null nerves. Vimentin instead binds integrin alpha5beta1, which regulates proliferation and differentiation later in regeneration, and may compensate for the absence of GFAP in mutant mice. GFAP might contribute to form macro-complexes to initiate mitogenic and differentiating signaling for efficient nerve regeneration.


Subject(s)
Cell Proliferation , Glial Fibrillary Acidic Protein/genetics , Glial Fibrillary Acidic Protein/physiology , Nerve Regeneration/genetics , Schwann Cells/physiology , Animals , Cell Differentiation/genetics , Cytoskeleton/metabolism , Extracellular Matrix/chemistry , Integrins/metabolism , Intermediate Filaments/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Nerve Crush/rehabilitation , Neurons/cytology , Neurons/physiology , Peripheral Nervous System/growth & development , Sciatic Nerve/injuries , Vimentin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...